Daniel L. Hertz
YOU?
Author Swipe
View article: Effect of Chemotherapy-Induced Peripheral Neuropathy Symptom Permanence on Patient's Preference to Alter or Continue Neurotoxic Chemotherapy Treatment
Effect of Chemotherapy-Induced Peripheral Neuropathy Symptom Permanence on Patient's Preference to Alter or Continue Neurotoxic Chemotherapy Treatment Open
PURPOSE Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect of neurotoxic chemotherapy that can persist for years after treatment and permanently diminish patient's long-term function and quality of life…
View article: Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges
Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges Open
Barriers to incorporating pharmacogenetics into routine clinical practice in the United States are well documented. Initial surveys by the Clinical Pharmacogenetics Implementation Consortium (CPIC) in 2009 and 2010 identified barriers acro…
View article: Mixed-methods Study of the Effect of Chemotherapy-induced Peripheral Neuropathy SymptomPermanence on Patient’s Willingness to Alter Neurotoxic Chemotherapy Treatment
Mixed-methods Study of the Effect of Chemotherapy-induced Peripheral Neuropathy SymptomPermanence on Patient’s Willingness to Alter Neurotoxic Chemotherapy Treatment Open
Purpose Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect from taxane and platinum chemotherapy, with symptoms that can persist for years after treatment and significantly diminish quality of life. Thi…
View article: Tolerance for chemotherapy-induced peripheral neuropathy among women with metastatic breast cancer: a discrete-choice experiment
Tolerance for chemotherapy-induced peripheral neuropathy among women with metastatic breast cancer: a discrete-choice experiment Open
Purpose To quantify preferences for chemotherapy-induced peripheral neuropathy (CIPN) risks and survival benefits of continuing neurotoxic chemotherapy and explore differences in preferences by race among women with metastatic breast cance…
View article: Factors influencing the decision to discontinue treatment due to chemotherapy-induced peripheral neuropathy among patients with metastatic breast cancer: a best–worst scaling
Factors influencing the decision to discontinue treatment due to chemotherapy-induced peripheral neuropathy among patients with metastatic breast cancer: a best–worst scaling Open
Purpose To measure the importance of factors that influence the decision to discontinue treatment due to chemotherapy-induced peripheral neuropathy (CIPN) among patients with metastatic breast cancer (mBC). Methods An online survey incorpo…
View article: A Guide for Implementing <i>DPYD</i> Genotyping for Systemic Fluoropyrimidines into Clinical Practice
A Guide for Implementing <i>DPYD</i> Genotyping for Systemic Fluoropyrimidines into Clinical Practice Open
The safety of systemic fluoropyrimidines (e.g., 5‐fluorouracil, capecitabine) is impacted by germline genetic variants in DPYD, which encodes the dihydropyrimidine dehydrogenase (DPD) enzyme that functions as the rate‐limiting step in the …
View article: Remote Monitoring of Chemotherapy-Induced Peripheral Neuropathy by the NeuroDetect iOS App: Observational Cohort Study of Patients With Cancer
Remote Monitoring of Chemotherapy-Induced Peripheral Neuropathy by the NeuroDetect iOS App: Observational Cohort Study of Patients With Cancer Open
Background Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating adverse effect of neurotoxic chemotherapy characterized by symptoms such as numbness, tingling, and weakness. Effective monitoring and detection of C…
View article: DPYD Genotype-guided Dose Optimization of 5-Fluorouracil in Individuals with Pancreatic Cancer
DPYD Genotype-guided Dose Optimization of 5-Fluorouracil in Individuals with Pancreatic Cancer Open
Systemic fluoropyrimidines (FP) including intravenous 5-fluorouracil (IV 5-FU) and its oral prodrug capecitabine are used to treat a variety of solid tumors such as pancreatic, colorectal, and breast cancer. National Comprehensive Cancer N…
View article: Patient-reported Strategies for Prevention and Treatment of Chemotherapy- induced Peripheral Neuropathy
Patient-reported Strategies for Prevention and Treatment of Chemotherapy- induced Peripheral Neuropathy Open
Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating toxicity of many drugs used in cancer treatment. There are numerous available strategies for preventing or treating CIPN, but few are guideline-recommended, due t…
View article: Remote Monitoring of Chemotherapy-Induced Peripheral Neuropathy by the NeuroDetect iOS App: Observational Cohort Study of Patients With Cancer (Preprint)
Remote Monitoring of Chemotherapy-Induced Peripheral Neuropathy by the NeuroDetect iOS App: Observational Cohort Study of Patients With Cancer (Preprint) Open
BACKGROUND Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating adverse effect of neurotoxic chemotherapy characterized by symptoms such as numbness, tingling, and weakness. Effective monitoring and detection of …
View article: Strategies for DPYD Testing Prior to Fluoropyrimidine Chemotherapy in the United States
Strategies for DPYD Testing Prior to Fluoropyrimidine Chemotherapy in the United States Open
Purpose Patients with dihydropyrimidine dehydrogenase (DPD) deficiency are at high risk for severe and fatal toxicity from fluoropyrimidine (FP) chemotherapy. Pre-treatment DPYD testing is standard of care in many countries, but not the Un…
View article: Recommendations for pharmacogenetic testing in clinical practice guidelines in the US
Recommendations for pharmacogenetic testing in clinical practice guidelines in the US Open
Purpose Pharmacogenetic testing can identify patients who may benefit from personalized drug treatment. However, clinical uptake of pharmacogenetic testing has been limited. Clinical practice guidelines recommend biomarker tests that the g…
View article: Nonlinear Mixed‐Effects Model of Z‐Endoxifen Concentrations in Tamoxifen‐Treated Patients from the CEPAM Cohort
Nonlinear Mixed‐Effects Model of Z‐Endoxifen Concentrations in Tamoxifen‐Treated Patients from the CEPAM Cohort Open
Tamoxifen is widely used in patients with hormone receptor‐positive breast cancer. The polymorphic enzyme CYP2D6 is primarily responsible for metabolic activation of tamoxifen, resulting in substantial interindividual variability of plasma…
View article: Incorporation of emergent symptoms and genetic covariates improves prediction of aromatase inhibitor therapy discontinuation
Incorporation of emergent symptoms and genetic covariates improves prediction of aromatase inhibitor therapy discontinuation Open
Objectives Early discontinuation is common among breast cancer patients taking aromatase inhibitors (AIs). Although several predictors have been identified, it is unclear how to simultaneously consider multiple risk factors for an individu…
View article: Risk of Toxicity From Topical <scp>5‐Fluorouracil</scp> Treatment in Patients Carrying <i>DPYD</i> Variant Alleles
Risk of Toxicity From Topical <span>5‐Fluorouracil</span> Treatment in Patients Carrying <i>DPYD</i> Variant Alleles Open
Patients carrying DPYD variant alleles have increased risk of severe toxicity from systemic fluoropyrimidine chemotherapy. There is a paucity of data regarding risk of toxicity from topical 5‐fluorouracil (5‐FU) treatment in these patients…
View article: Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221
Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221 Open
Background: Prior work suggests that patients with vitamin D insufficiency may have a higher risk of chemotherapy-induced peripheral neuropathy (CIPN) from paclitaxel. The objective of this study was to validate vitamin D insufficiency as …
View article: Patient Perceptions of Altering Chemotherapy Treatment Due to Peripheral Neuropathy
Patient Perceptions of Altering Chemotherapy Treatment Due to Peripheral Neuropathy Open
Purpose Clinical practice guidelines recommend altering neurotoxic chemotherapy treatment in patients experiencing intolerable chemotherapy-induced peripheral neuropathy (CIPN). The primary objective of this survey was to understand patien…
View article: Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221
Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221 Open
Background Chemotherapy-induced peripheral neuropathy (CIPN) is a treatment-limiting and debilitating neurotoxicity of many commonly used anti-cancer agents, including paclitaxel. The objective of this study was to confirm the previously f…
View article: Effects of <i>CYP3A4</i> and <i>CYP2C9</i> Genotype on Systemic Anastrozole and Fulvestrant Concentrations in SWOG S0226
Effects of <i>CYP3A4</i> and <i>CYP2C9</i> Genotype on Systemic Anastrozole and Fulvestrant Concentrations in SWOG S0226 Open
Objective & methods: This study tested associations of genotype-predicted activity of CYP3A4, other pharmacogenes, SLC28A7 (rs11648166) and ALPPL2 (rs28845026) with systemic concentrations of the endocrine therapies anastrozole and fulvest…
View article: Response to the FDA Decision Regarding <i>DPYD</i> Testing Prior to Fluoropyrimidine Chemotherapy
Response to the FDA Decision Regarding <i>DPYD</i> Testing Prior to Fluoropyrimidine Chemotherapy Open
Fluoropyrimidine (FP) chemotherapy is associated with severe, life‐threatening toxicities, particularly among patients who carry deleterious germline variants in the DPYD gene. Pretreatment DPYD testing is standard of care throughout most …
View article: Confirmatory <scp><i>DPYD</i></scp> Testing in Patients Receiving Fluoropyrimidines Who are Suspected <scp><i>DPYD</i></scp> Variant Carriers Based on a Genetic Data Repository
Confirmatory <span><i>DPYD</i></span> Testing in Patients Receiving Fluoropyrimidines Who are Suspected <span><i>DPYD</i></span> Variant Carriers Based on a Genetic Data Repository Open
Using pharmacogenetics (PGx) to inform clinical decision making can benefit patients but clinical use of PGx testing has been limited. Existing genetics data obtained in the course of research could be used to identify patients who are sus…
View article: Supplementary Figures and Tables from Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer
Supplementary Figures and Tables from Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer Open
Supplementary Figures and Tables for Clinical and Genome Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer Figure S1. Diagram of Data Collection Pipeline. Table S1. EORTC-CIPN20 questionnaire. Figu…
View article: Supplementary Table 3 from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Supplementary Table 3 from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy Open
Most Highly Enriched Canonical Pathways
View article: Data from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Data from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy Open
Purpose: Discovery of SNPs that predict a patient's risk of docetaxel-induced neuropathy would enable treatment individualization to maximize efficacy and avoid unnecessary toxicity. The objectives of this analysis were to discover SNPs as…